4//SEC Filing
Crane Alan L 4
Accession 0000899243-20-019884
CIK 0001807901other
Filed
Jul 20, 8:00 PM ET
Accepted
Jul 21, 7:44 PM ET
Size
33.7 KB
Accession
0000899243-20-019884
Insider Transaction Report
Form 4
Crane Alan L
Director10% Owner
Transactions
- Conversion
Common Stock
2020-07-21+272,046→ 3,055,938 total(indirect: See footnote) - Conversion
Common Stock
2020-07-21+9,736→ 109,373 total(indirect: See footnote) - Purchase
Common Stock
2020-07-21$18.00/sh+34,863$627,534→ 3,090,801 total(indirect: See footnote) - Award
Stock Option (right to buy)
2020-07-17+13,997→ 13,997 totalExercise: $18.00Exp: 2030-07-16→ Common Stock (13,997 underlying) - Conversion
Common Stock
2020-07-21+99,637→ 99,637 total(indirect: See footnote) - Purchase
Common Stock
2020-07-21$18.00/sh+1,248$22,464→ 110,621 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2020-07-21−14,196,152→ 0 total(indirect: See footnote)→ Common Stock (2,783,892 underlying) - Conversion
Common Stock
2020-07-21+2,783,892→ 2,783,892 total(indirect: See footnote) - Conversion
Common Stock
2020-07-21+21,133→ 70,158 total - Purchase
Common Stock
2020-07-21$18.00/sh+14,000$252,000→ 84,158 total - Conversion
Series A Preferred Stock
2020-07-21−508,090→ 0 total(indirect: See footnote)→ Common Stock (99,637 underlying) - Conversion
Series B Preferred Stock
2020-07-21−1,387,268→ 0 total(indirect: See footnote)→ Common Stock (272,046 underlying) - Conversion
Series B Preferred Stock
2020-07-21−49,652→ 0 total(indirect: See footnote)→ Common Stock (9,736 underlying) - Conversion
Series B Preferred Stock
2020-07-21−107,768→ 0 total→ Common Stock (21,133 underlying)
Holdings
- 336,314(indirect: By Trust)
Common Stock
Footnotes (5)
- [F1]The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]The reportable securities are owned directly by Polaris Partners VIII, L.P. ("PP VIII"). Polaris Partners GP VIII, L.L.C. ("PPGP VIII") is the general partner of PP VIII. The Reporting Person, a member of the Issuer's Board of Directors, is an interest holder of PPGP VIII. Each of David Barrett, Brian Chee, Amir Nashat and Bryce Youngren are the managing members of PPGP VIII (collectively, the "Managing Members"). Each of the Reporting Person and the Managing Members, in their respective capacities with respect to PPGP VIII, may be deemed to have shared voting and dispositive power over the shares held by PP VIII. Each of PPGP VIII, the Reporting Person and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
- [F3]The reportable securities are owned directly by Polaris Entrepreneurs' Fund VIII, L.P. ("PEF VIII"). PPGP VIII is the general partner of PEF VIII. The Reporting Person, a member of the Issuer's Board of Directors, is an interest holder of PPGP VIII. Each of the Reporting Person and the Managing Members, in their respective capacities with respect to PPGP VIII, may be deemed to have shared voting and dispositive power over the shares held by PEF VIII. Each of PPGP VIII, the Reporting Person and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
- [F4]Represents shares purchased through a directed share program in connection with the initial public offering of Pandion Therapeutics, Inc.'s common stock, which closed on July 21, 2020. These shares of common stock were purchased at the public offering price of $18.00 per share.
- [F5]This option award was granted on July 17, 2020. The shares underlying the award vest in equal monthly installments following July 17, 2020 through July 17, 2023, subject to the reporting person's continued service on each applicable vesting date.
Documents
Issuer
Pandion Therapeutics, Inc.
CIK 0001807901
Entity typeother
Related Parties
1- filerCIK 0001294361
Filing Metadata
- Form type
- 4
- Filed
- Jul 20, 8:00 PM ET
- Accepted
- Jul 21, 7:44 PM ET
- Size
- 33.7 KB